These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 26182965)
1. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. Chittenden SJ; Hindorf C; Parker CC; Lewington VJ; Pratt BE; Johnson B; Flux GD J Nucl Med; 2015 Sep; 56(9):1304-9. PubMed ID: 26182965 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases. Yoshida K; Kaneta T; Takano S; Sugiura M; Kawano T; Hino A; Yamamoto T; Shizukuishi K; Kaneko M; Zurth C; Inoue T Ann Nucl Med; 2016 Aug; 30(7):453-60. PubMed ID: 27272279 [TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Carrasquillo JA; O'Donoghue JA; Pandit-Taskar N; Humm JL; Rathkopf DE; Slovin SF; Williamson MJ; Lacuna K; Aksnes AK; Larson SM; Scher HI; Morris MJ Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1384-93. PubMed ID: 23653243 [TBL] [Abstract][Full Text] [Related]
5. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485 [TBL] [Abstract][Full Text] [Related]
7. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825 [TBL] [Abstract][Full Text] [Related]
8. Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer. Pratt BE; Hindorf C; Chittenden SJ; Parker CC; Flux GD Nucl Med Commun; 2018 Feb; 39(2):125-130. PubMed ID: 29189490 [TBL] [Abstract][Full Text] [Related]
10. Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer. Dauer LT; Williamson MJ; Humm J; O'Donoghue J; Ghani R; Awadallah R; Carrasquillo J; Pandit-Taskar N; Aksnes AK; Biggin C; Reinton V; Morris M; St Germain J Health Phys; 2014 Apr; 106(4):494-504. PubMed ID: 24562070 [TBL] [Abstract][Full Text] [Related]
11. Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. Denis-Bacelar AM; Chittenden SJ; McCready VR; Divoli A; Dearnaley DP; O'Sullivan JM; Johnson B; Flux GD Br J Radiol; 2018 Apr; 91(1084):20170795. PubMed ID: 29293372 [TBL] [Abstract][Full Text] [Related]
12. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913 [TBL] [Abstract][Full Text] [Related]
13. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596 [TBL] [Abstract][Full Text] [Related]
14. Detection and quantification of Mínguez P; Gómez de Iturriaga A; Fernández IL; Rodeño E Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):20-27. PubMed ID: 28645684 [TBL] [Abstract][Full Text] [Related]
17. A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. Pacilio M; Ventroni G; Cassano B; Ialongo P; Lorenzon L; Di Castro E; Recine F; Sternberg CN; Mango L Ann Nucl Med; 2016 Feb; 30(2):163-8. PubMed ID: 26613714 [TBL] [Abstract][Full Text] [Related]
18. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Bruland ØS; Nilsson S; Fisher DR; Larsen RH Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6250s-6257s. PubMed ID: 17062709 [TBL] [Abstract][Full Text] [Related]
19. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis. Abou DS; Ulmert D; Doucet M; Hobbs RF; Riddle RC; Thorek DL J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26683407 [TBL] [Abstract][Full Text] [Related]
20. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]